DERP2 Antibody
Description
Introduction to Der p 2 Antibody
Der p 2 is a major allergen from the house dust mite Dermatophagoides pteronyssinus, responsible for triggering IgE-mediated allergic reactions in 71–80% of sensitized individuals . Antibodies targeting Der p 2 play critical roles in both diagnostic and therapeutic contexts, particularly in allergic asthma, rhinitis, and atopic dermatitis.
IgE Epitope Mapping
Der p 2 contains five major conformational IgE-binding epitopes identified through alanine-scanning mutagenesis (N10, E25, K77, K96, E102) . Among these, K96A and E102A mutants demonstrated the most significant reduction in IgE reactivity (up to 90% loss) .
| Key IgE Epitopes | IgE Reactivity Reduction (%) |
|---|---|
| N10A | 30–45 |
| E25A | 40–55 |
| K77A | 35–50 |
| K96A | 85–90 |
| E102A | 70–80 |
These mutants retain structural stability, making them candidates for hypoallergenic vaccines .
Cross-Reactivity and Antibody Diversity
Der p 2 variants (e.g., Der p 2.0101, Der p 2.0104) exhibit region-specific IgE-binding patterns. For example:
-
Der p 2.0104 binds IgE more effectively in Bangkok sera than Perth sera .
-
Mouse anti-Der p 2.0101 IgG antibodies show high cross-reactivity but poor binding to other variants .
Hypoallergenic Vaccines
-
K96A/E102A Mutants: Induce IgG antibodies that inhibit 90% of IgE binding to wild-type Der p 2 in murine models .
-
Der p 2-FlaB Fusion Protein: Reduces airway hyperresponsiveness and eosinophil infiltration by 60–70% in asthma models .
| Therapeutic Strategy | Efficacy (Reduction in Symptoms) | Key Mechanism |
|---|---|---|
| K96A/E102A Hypoallergens | 85–90% IgE inhibition | Block IgE binding sites |
| Der p 2-FlaB Fusion | 60–70% airway inflammation | Suppresses Th2 responses |
| Carrier-bound Peptides | 80% basophil activation inhibition | Tolerogenic IgG induction |
Immunotherapy Biomarkers
-
Der p 2-specific IgE: Positively correlates with clinical efficacy of subcutaneous immunotherapy (SCIT) (r = 0.72, P < 0.05) .
-
Serum Periostin: Linked to Der p 2 IgE levels, serving as a prognostic marker for SCIT outcomes .
Clinical Significance
-
Diagnostic Utility: Der p 2-specific IgE levels predict sensitization with 80.5% sensitivity (wheal size ≥4.5 mm) .
-
Asthma Risk: Der p 2 sensitization increases pediatric asthma risk by 3.5-fold compared to Der p 1 .
-
TLR4 Dependence: Der p 2 triggers Th2 responses independently of TLR4 signaling, complicating traditional immune pathway targeting .
Recent Advances
-
Structural Studies: X-ray crystallography revealed a high-affinity IgE epitope involving residues Gly101 and Tyr102 on Der p 2 (K_D = 2.97 × 10⁻¹⁰ M) .
-
Peptide Vaccines: Carrier-bound Der p 2 peptides (P1–P5) reduce T-cell proliferation by 50% while inducing blocking IgG antibodies .
Future Directions
Current research focuses on:
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
The DERP2 antibody is generated by immunizing a rabbit with recombinant Dermatophagoides pteronyssinus DERP2 (amino acids 18-146). This process stimulates the rabbit's B lymphocytes to produce specific IgG antibodies. The polyclonal DERP2 antibody is then rigorously purified from the rabbit serum using protein A/G techniques.
This DERP2 antibody is suitable for detecting Dermatophagoides pteronyssinus DERP2 protein in ELISA and Western blot (WB) experiments.
Dermatophagoides pteronyssinus DERP2 (Der p 2) protein is an MD-2 mimetic found in the intestine and feces of mites. It has been demonstrated to promote lipopolysaccharide-driven TLR4 signaling and Th2 polarization. Beyond its role in innate immunity activation, Der p 2 interacts with B-lymphocytes, engaging adaptive immunity in the response.
